FDA Delays Decision on Celgene's Blood Cancer Drug Revlimid

Drug Industry Daily
KEYWORDS Drug Approvals / FDA
A A

The FDA has delayed its decision on Celgene’s oral blood cancer drug Revlimid, pending further review of the firm’s risk management plan for the drug, but Celgene hastened to say that the delay is only due to a paperwork backup.

To View This Article:

Login

Subscribe To Drug Industry Daily